Moclobemide treatment of resistant depression in a patient with vascular dementia

Human Psychopharmacology

Volumn 11, Issue 1, 1996, Pages 67-68

  Barak, Yoram ^a   Suholitsky, Hanna ^a   Noy, Shlomo ^b  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Depression; Moclobemide; Vascular dementia

Indexed keywords

FLUVOXAMINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR;

AGED; ARTICLE; CASE REPORT; DEMENTIA; DEPRESSION; DRUG EFFICACY; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0030065850     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199601)11:1<67::AID-HUP740>3.0.CO;2-8     Document Type: Article

References (16)

1. American Psychiatric Association (1994). Diagnostic Criteria from DSM-IV tm. APA, Washington DC.
2. Angst, J., Freeman, H. L., Montgomery, S. A., Priest, R. G. and Racagni, G. (1992). RIMA: A new concept in the treatment of depression. Psychopharmacology, 106 (Suppl.).
3. Bech, P. (1993). Acute therapy of depression. Journal of Clinical Psychiatry, 54, 18-27.
4. Chan-Palay, V. (1991). Depression and dementia in Parkinson's disease - catecholamine changes in the locus ceruleus - basis for therapy. Dementia, 2, 7-17.
5. Chan-Palay, V. (1992). Depression and senile dementia of the Alzheimer type: a role for moclobemide. Psychopharmacology, 106, S137-S139.
6. Da Prada, M., Kettler, R., Keller, H. H. and Haefely, W. E. (1983). Neurochemical effects in vitro and in vivo of the antidepressants Ro 11-1163, a specific and short-acting MAO-A inhibitor. Modern Problems in Pharmacopsychiatry, 19, 231-237.
7. Gerson, S. C., Plotkin, D. A. and Jarvik, L. F. (1988). Antidepressant drug studies, 1964-1986; empirical evidence for aging patients. Journal of Clinical Psychopharmacology, 8, 311-322.
8. Helmchen, H. (1991). Therapy resistance in depression. In: Problems of Psychiatry in General Medicine, Gastpar, M. and Kielholz, P. (Eds), Hogrefe and Huber, New York, pp. 97-106.
9. Jenike, M. A. (1985). Handbook of Geriatric Psychopharmacology. PSG, Publishing Co., Littleton, MA.
10. Jeste, D. V. and Krull, A. J. (1991). Behavioral problems associated with dementia: Diagnosis and treatment. Geriatrics, 46, 28-34.
11. Karasu, T. B., Docherty, J. P. and Gelenberg, A. (1993). Practice guidelines for major depressive disorder in adults. American Journal of Psychiatry, 150, 11-12.
12. Merriam, A. E., Aronson, M. K., Gason, P., Wey, S. L. and Katz, I. (1988). The psychiatric symptoms of Alzheimer's disease. Journal of the American Geriatric Society, 36, 7-12.
13. Pancheri, P., Dell-Chiaie, R., Donnini, M., Seripa, S., Gambino, C., Vicario, E. and Trillo, E. (1994). Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine. Clinical Neuropharmacology, 17 (Suppl.), 58-73.
14. Robinson, D. and Kurtz, N. (1987). MAO-I drugs. In: Psychopharmacology: the Third Generation of Progress Meltzer, H. Y. (Ed.), Raven Press, New York, pp. 1297-1304.
15. Tiller, J. W. G. (1992). Post-stroke depression. Psychopharmacology, 106, S130-S133.
16. Wolfe, N., Linn, R. and Babikian, V. L. (1990). Frontal systems impairment following multiple lacunar infarcts. Archives of Neurology, 47, 129-132.